IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses.

Keyphrases

• Th17 Response 100%
• Th1 Response 100%
• Central Nervous System Autoimmunity 100%
• IL-27p28 100%
• T Helper 17 (Th17) 60%
• Experimental Autoimmune Encephalomyelitis 40%
• Experimental Autoimmune Uveitis 40%
• Glycoprotein 130 (gp130) 40%
• Central Nervous System 20%
• Transcription Factor 20%
• Interleukin-6 20%
• T Cells 20%
• Overexpression 20%
• Mechanistic Studies 20%
• Disease Prevention 20%
• Immune Response 20%
• Autoimmune Disease 20%
• Therapeutic Targeting 20%
• Th1 Cells 20%
• Multiple Sclerosis 20%
• Therapeutic Implications 20%
• Model Experimental 20%
• Uveitis 20%
• Effector Responses 20%
• Interleukin-27 (IL-27) 20%
• Tissue Infiltration 20%
• Th17 Effector Cells 20%
• Disease Reversal 20%
• Effector Pathways 20%
• Th1 Effector Cells 20%

Immunology and Microbiology

• Central Nervous System 100%
• Autoimmunity 100%
• Experimental Autoimmune Encephalomyelitis 66%
• Autoimmune Uveitis 66%
• Glycoprotein Gp 130 66%
• Transcription Factor 33%
• Cytokine 33%
• T Cell 33%
• Interleukin 6 33%
• Immune Response 33%
• Lineage 33%
• Th17 Cell 33%
• Autoimmune Disease 33%
• Th1 Cell 33%
• Multiple Sclerosis 33%
• Experimental Model 33%
• Uveitis 33%
• Effector Cell 33%